Sakai T, Noguchi M, Kisiel W
Department of Pathology, University of New Mexico School of Medicine, Albuquerque.
Haemostasis. 1990;20(3):125-35. doi: 10.1159/000216119.
Activation of blood coagulation and local fibrin deposition may contribute to tumor metastasis. We have examined the ability of four human tumor cell lines (COLO 205, HepG2, J82 and CAPAN-2) to augment the conversion of prothrombin to thrombin by factor Xa and calcium in the presence and absence of exogenous factor Va. Using a chromogenic substrate assay to assess thrombin formation, we observed that all the above cell lines accelerated prothrombin activation in the absence of exogenous factor Va. The order of effectiveness was COLO 205 greater than HepG2 greater than J82 greater than CAPAN-2. In the absence of cells, no detectable thrombin formation occurred. Pretreatment of COLO 205 and HepG2 cells with anti-human factor V IgG inhibited prothrombin activation in a dose-dependent manner, but was without effect in J82 and CAPAN-2 incubation mixtures. Factor V coagulant activity was observed in COLO 205 and HepG2 cells as well as their culture media, but was not detected in J82 and CAPAN-2 cells or their culture media. Biosynthetic labeling and immunoprecipitation studies revealed that COLO 205 and HepG2 cells constitutively synthesized factor V or a factor-V-like molecule that comigrated with human factor V/Va on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. All four tumor cell lines exhibited saturation binding of exogenous human factor Va resulting in a dose-dependent enhancement of their ability to augment prothrombin activation. Our results indicate that these tumor cells can readily assemble a functional cell surface prothrombinase complex that may be important in fibrin deposition associated with the growth and metastatic progression of these, and perhaps, other tumors.
血液凝固的激活和局部纤维蛋白沉积可能有助于肿瘤转移。我们检测了四种人类肿瘤细胞系(COLO 205、HepG2、J82和CAPAN - 2)在有和没有外源性因子Va的情况下,增强因子Xa和钙将凝血酶原转化为凝血酶的能力。使用发色底物分析法评估凝血酶的形成,我们观察到在没有外源性因子Va的情况下,上述所有细胞系都加速了凝血酶原的激活。有效性顺序为COLO 205大于HepG2大于J82大于CAPAN - 2。在没有细胞的情况下,未发生可检测到的凝血酶形成。用抗人因子V IgG预处理COLO 205和HepG2细胞以剂量依赖性方式抑制凝血酶原激活,但对J82和CAPAN - 2孵育混合物没有影响。在COLO 205和HepG2细胞及其培养基中观察到因子V促凝活性,但在J82和CAPAN - 2细胞及其培养基中未检测到。生物合成标记和免疫沉淀研究表明,COLO 205和HepG2细胞组成性地合成因子V或一种在十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳上与人因子V/Va共迁移的类因子V分子。所有四种肿瘤细胞系对外源性人因子Va均表现出饱和结合,导致其增强凝血酶原激活能力的剂量依赖性增强。我们的结果表明,这些肿瘤细胞可以很容易地组装一个功能性细胞表面凝血酶原酶复合物,这可能在与这些肿瘤以及或许其他肿瘤的生长和转移进展相关的纤维蛋白沉积中起重要作用。